KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kailera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.43+0.18 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
About Kailera Therapeutics
Pharmaceutical Preparations, SIC 2834
Kailera Therapeutics, Inc. is listed on Nasdaq under the ticker KLRA, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Kailera Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 180 Third Avenue, 4th Floor 02451
- Phone
- (508) 440-9475
- Website
- kailera.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- KLRA
- Exchange
- Nasdaq
- IPO date
- Apr 17, 2026
- Shares outstanding
- 130M, Aug 6, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2096997
- CUSIP
- 482931102
- ISIN
- US4829311020
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ronald C. Renaud JR | CEO & President, Director | 38,094 |
| Nur Nicholson | Chief Technology Officer | – |
| Kathleen Tregoning | See Remarks | – |
| Paul D. Burgess | See Remarks | – |
| Paula Cloghessy | Chief People Officer | – |
| Jamie Beth Coleman | Chief Commercial Officer | – |
| Scott Akamine | Chief Legal Officer | – |
| Scott M. Wasserman | Chief Medical Officer | – |
| Douglas W. Pagan | Chief Financial Officer | – |
| Frank Clyburn | Director | – |
| Christopher Hite | Director | – |
| John F. Milligan | Director | – |
| Martin Mackay | Director | – |
| Adam Koppel | Director | 16,875,000 |
| Andrew T. Kaplan | Director | 17,857,143 |
| Yuting Liu | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |